Validation of diagnosis criteria for acquired sensory neuronopathy. a francophone multicenter study

Details

Serval ID
serval:BIB_63124ED8578B
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Validation of diagnosis criteria for acquired sensory neuronopathy. a francophone multicenter study
Title of the conference
Meeting of the Peripheral Nerve Society
Author(s)
Antoine J.-.C., Abba K., Franques J., Pouget J., Delmont E., Kuntzer T., Petiot P., Gervais-Bernard H., Echaniz-Laguna A., Creange A., Mathis S., Camdessanche J.-.P.
Address
Potomac, Maryland, June 25-29, 2011
ISBN
1085-9489
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
16
Series
Journal of the Peripheral Nervous System
Pages
S3-S4
Language
english
Notes
Publication type : Meeting Abstract
Abstract
Recently published criteria using clinical (ataxia or asymmetrical distribution at onset or full development, and sensory loss not restricted to the lower limbs) and electrophysiological items (less than two abnormal lower limb motor nerves and at least an abolished SAP or three SAP below 30% of lower limit of normal in the upper limbs) were sensitive and specific for the diagnosis of sensory neuronopathy (SNN) (Camdessanche et al., Brain, 2009). However, these criteria need to be validated on a large multicenter population. For this, a database collecting cases from fifteen Reference Centers for Neuromuscular diseases in France and Switzerland is currently developed. So far, data from 120 patients with clinically pure sensory neuropathy have been collected. Cases were classified independently from the evaluated criteria as SNN (53), non-SNN (46) or suspected SNN (21) according to the expert's diagnosis. Using the criteria, SNN was possible in 83% (44/53), 23.9% (11/46) and 71.4% (15/21) of cases, respectively. In the non-SSN group, half of the patients with a diagnosis of possible SSN had an ataxic form of inflammatory demyelinating neuropathy. In the SNN group, half of those not retained as possible SNN had CANOMAD, paraneoplasia, or B12 deficiency. In a second step, after application of the items necessary to reach the level of probable SNN (no biological or electrophysiological abnormalities excluding SNN; presence of onconeural antibody, cisplatin treatment, Sj ¨ ogren's syndrome or spinal cord MRI high signal in the posterior column), a final diagnosis of possible or probable SNN was obtained in, respectively, 90.6% (48/53), 8.8% (4/45), and 71.4% (15/21) of patients in the three groups. Among the 5 patients with a final non-SNN but initial SNN diagnosis, 3 had motor conduction abnormalities (one with CANOMAD) and among the 4 patients with a final SNN but initial non-SSN diagnosis, one had anti-Hu antibody and one was discussed as a possible ataxic CIDP. These preliminary results confirm the sensitivity and specificity of the proposed criteria for the diagnosis of SNN.
Web of science
Create date
01/09/2011 13:22
Last modification date
20/08/2019 15:19
Usage data